AC 7700: Clinical Trials

11 completed. 8 Phase 1, 2 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 8
Phase 2	2	Completed 2
Phase 3	1	Completed 1

Follow AC 7700: new trials by email Literature Review of AC 7700 trials Research Report on AC 7700

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Ombrabulin (AVE8062), Placebo, Paclitaxel - Ovarian Cancer Recurrent	Phase 2	Completed	Sanofi	154	2011-05-01	2015-12-21
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer ombrabulin (AVE8062), placebo - Non-small Cell Lung Cancer	Phase 2	Completed	Sanofi	176	2011-02-01	2015-12-21
A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors Ombrabulin (AVE8062), Paclitaxel, Carboplatin - Advanced Solid Tumors	Phase 1	Completed	Sanofi	18	2011-01-01	2015-10-30
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors Ombrabulin (AVE8062), bevacizumab - Neoplasms, Malignant	Phase 1	Completed	Sanofi	39	2010-09-01	2014-12-03
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors OMBRABULIN (AVE8062), cisplatin, docetaxel - Neoplasms, Malignant	Phase 1	Completed	Sanofi	11	2010-05-01	2013-10-16
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors ombrabulin (AVE8062), cisplatin - Neoplasms, Malignant	Phase 1	Completed	Sanofi	12	2010-03-01	2011-06-13
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor Ombrabulin (AVE8062) - Neoplasms, Malignant	Phase 1	Completed	Sanofi	3	2010-01-01	2011-12-21
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors ombrabulin (AVE8062) - Solid Tumor	Phase 1	Completed	Sanofi	15	2009-09-01	2014-09-19
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor OMBRABULIN (AVE8062) - Neoplasms	Phase 1	Completed	Sanofi	71	2008-07-01	2013-03-11
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies OMBRABULIN (AVE8062), Placebo - Sarcoma	Phase 3	Completed	Sanofi	355	2008-06-01	2015-12-21
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors AVE8062, Docetaxel - Advanced Neoplastic Disease	Phase 1	Completed	Sanofi	58	2006-06-01	2013-07-25

Conditions studied

Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Sarcoma (1)

Sponsors

Sanofi (11)

Countries

France (5)  ·  Italy (5)  ·  Japan (4)  ·  Belgium (3)  ·  United States (3)  ·  Germany (2)  ·  Poland (2)  ·  Russia (2)  ·  Serbia (2)  ·  Spain (2)  ·  Ukraine (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Brazil (1)  ·  Chile (1)

Results publications

PMID 24477603, PMID 24714750, PMID 24898305, PMID 25864104, PMID 29514256, PMID 37989482

NIH funding

2005 (1), 2008 (1), 2009 (1)